Potential of using structured data from clinical trials and routine for AI and radiomics research

Dr. Nils Grosse Hokamp shares his experience of using mint Lesion™ at the University Hospital Cologne in this brief interview. He talks about how they have expanded their usage of mint Lesion™ over the years, how it has changed their clinical studies, and his view on the potential of structured data for research.

Related Resources

Related Resources

Study Analyzing the Tumor Growth Rate as a Prognostic Biomarker in Lymphoma Patients Under CAR T-Cell Therapy

University Hospital Munich (LMU): Study Analyzing the Tumor Growth Rate as a Prognostic Biomarker in Lymphoma Patients Under CAR T-Cell Therapy

A recent study[1] conducted by researchers at the University Hospital Munich (LMU) investigated the role of tumor growth rate (TGR) in predicting the…

A picture of a person looking at a brain scan and the interface of mint Lesion™  on a computer

Advancing Neuro-Oncology Assessments: Mint Medical to Integrate Newly Published RANO 2.0 Criteria into mint Lesion™

Glioblastomas and other gliomas are the most common malignant primary brain tumor types, yet few effective therapies are available. Clinical research…

A picture of radiologists looking at a screen showing the restaging of the HNSCC

Study Highlights the Potential of Radiomics in Medical Intervention

A recent study conducted by the Medical University of Innsbruck highlights the potential of radiomics in exploring the impacts of Radiochemotherapy…